Work

Hypersomnia following COVID-19 infection or vaccination: a case series and response to low-dose aripiprazole

Year: 2026
Type: article
Abstract: Sleep disturbances post-COVID-19 are increasingly recognized as one of the most common symptoms. While insomnia is the most frequently reported sleep disorder post-COVID-19, excessive sleep duration and central hypersomnias have also emerged as significant post-acute sequelae. Here, we present a clinical series of ten patients exhibiting sleep disturbances after COVID-19 infection or vaccination. Group A consists of seven adolescents who developed prolonged sleep duration (exceeding their baseline by at least 2 hours) following a COVID-19 infection. Group B includes three cases: one patient with exacerbated delayed sleep–wake phase disorder (DSWPD) post-infection, and two patients who developed central hypersomnias (idiopathic hypersomnia and Narcolepsy Type 1) subsequent to COVID-19 vaccination. For the seven patients with post-infectious prolonged sleep in Group A and for the DSWPD patient in Group B, pharmacological intervention with low-dose aripiprazole (mean final dose 1.4 mg) yielded robust clinical improvements. Recognizing these hypersomnia phenotypes and utilizing targeted therapies like low-dose aripiprazole is critical for restoring daily functioning and providing sustained support for individuals afflicted with Long COVID.
Language: English
Field: Psychology
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236253322
FWCI:
Cites: 29
Cited by:
Related to: 10
Parts: 2